Session

Multidisciplinary perspectives on managing bladder cancer: Hope is on the horizon

Industry session by PEERVOICE

  • Location:
    Room Stockholm, North Hall (Level 1)
  • Chair:
     M. Rouprêt, Paris (FR)
  • Aims and objectives of this session

    Although options for management of advanced bladder cancer have been limited, we are beginning to see data for several novel cancer immunotherapy treatment options—each of which has a distinct mechanism of action, pattern of response, and adverse event profile. This symposium will provide expert insights into the role of the immune system in cancer pathogenesis, current and emerging treatment options, and practical strategies for managing bladder cancer within a multidisciplinary framework.

    This activity is supported by an educational grant from F. Hoffmann-La Roche Ltd.

    Independent Medical Education (IME)

    This IME activity is organised by PeerVoice. This activity provides content that is evidence-based, balanced and free from commercial bias, with a primary objective to improve learner competence and patient care.

Introduction: Multidisciplinary perspectives on managing bladder cancer
 M. Rouprêt, Paris (FR)
Rationale for cancer immunotherapy in bladder cancer: What do we know?
 J. Puente, Madrid (ES)
Clinical data for immunotherapy in bladder cancer: What do the data tell us?
 A. Necchi, Milan (IT)
Putting data and theory into practice: What is the function of a multidisciplinary team?
 
Panel:
 A. Necchi, Milan (IT)
 
 
 J. Puente, Madrid (ES)
 
 
 M. Rouprêt, Paris (FR)
Conclusions and audience questions
 
Panel:
 A. Necchi, Milan (IT)
 
 
 J. Puente, Madrid (ES)
 
 
 M. Rouprêt, Paris (FR)